Foreword: recently, the iridium nitroglycerin (ii) of hydrochlorate, developed by the hin shwe medicine
Hereinafter referred to as elettronics (ii)
Joint (5-fu) and (lv) have been successful in obtaining formal approval from the national drug supervisory authority (nmpa) for non-removable terminal or transmissible patients who have failed in their previous base chemotherapy treatment. The approval of the drug demonstrates nmpa's recognition of its quality and efficacy, opening a new chapter in the treatment of patients with advanced pancreas cancer. Subsequently, on 30 january 2024, the first ili tikthong (ii) prescription was introduced at the jenzi hospital, affiliated with the medical school of shanghai university of transport。
First prescription to help treat chinese pancreatic cancer
The road to exploration for advanced pancreas cancer second-line treatment was rugged, and on 29 december 2023, the ili tektokron (ii) was officially approved for listing by nmpa, bringing new options for second-line treatment for patients with advanced pancreas cancer. On 30 january 2024, the kanzi hospital, affiliated to the medical school of shanghai university of transport, opened the first national prescription for ili tektokron (ii). The emergence of the first prescription marked the formal application of ili tikang (ii) to chinese pancreas cancer patients, which is more accompanied by evidence-based evidence from the chinese population. Believe that as more clinical experience is built up in the future, the elettropics (ii) can bring more survival benefits to more patients
Figure 1: the first elettropine quality (ii) prescription in the country was issued by the jenzi hospital, affiliated with the medical school of shanghai university of transport
One-way circuit, elytecongent (ii) breaks through the second-line treatment bottleneck for pancreas cancer
Pancreatic cancer is an extremely malignant tumour of the digestive system. Early pancreas cancers are characterized by no visible clinical symptoms and signs, difficulties in identifying patients in a timely manner, often at an advanced stage of diagnosis, and loss of surgery opportunities. Even if the patient is surgically excised, the survival rate is below 20 per cent1 for five years, and approximately 60 per cent of the patients undergo long-range transfers and local relapses within one year of the procedure. Chemotherapy continues to be the main treatment for patients with pancreas cancer who are unable to perform the root surgery. Clinical gisitabin is now a standard treatment programme for advanced pancreas cancer, but it is less effective. In the second-line treatment that has progressed after treatment in gisitabin, clinical choices are extremely limited and there is an urgent need for clinicians to explore new treatment options to meet clinical needs。
In the classic chemotherapy programme for pancreas cancer, elitikon is an important component. Using its unique prescription design screening and process development, the hs pharmaceutical has been successful in developing the elettropic lipids of high-load and encapsulation rates, and their stability has been impressive. Also, the surface area of the lipids is large enough to provide a better spatial barrier, which effectively reduces the adsorption of the mercurics on the surface of the lipids. This technique also avoids the identification and ingestion of a mesh-based internal skin system, thus prolonging the cycling time of the drug in the body. In addition, the particle size of the lipids is controlled below 100 nm, which, while reducing the ingestion of the mesh inner cortex system, also improves the distribution and metabolism of drugs in the body as well as in the tumours and ultimately achieves the goal of efficiency reduction. The unique “gold triangle” of the drug addresses the problems faced by the clinical use of common ili tikang formulations and offers better treatment options for patients with advanced pancreas cancer。
The pan-heroic-1 study has brought new options for second-line treatment for advanced pancreas cancer patients
The pan-heroic-1 study, led by professor qin qin qin of the indoshan hospital, affiliated to the chinese university of pharmacy, and professor wang wei of the inji hospital, affiliated to the shanghai university of transport, is a multi-centre, random, blind, parallel cross-check iii clinical trial, which includes 298 cases of terminal or non-resistible pancreatic cancers in the first line of gisitabin treatment and is randomly divided into test and control groups (1. 1). The main research endpoints are total survival periods (os), secondary studies include no progress survival periods (pfs), objective mitigation rates (orrs), etc. As of 18 november 2021, the median time for os data analysis was 12. 81 months。
Figure 2 pan-heroic-1 research design
The results of the study showed that the median ilitrocorporate (ii) patient was os up to 7. 39 months, a significant extension of 2. 4 months and a 37 per cent reduction in the risk of death for the more insolent group, a significant extension of 2. 73 months (4. 21 months vs 1. 48 months) for the medium pfs and a 64 per cent reduction in the progress of disease or death risk。
Figure 3 results of pan-heroic-1 study os, pfs
In terms of safety, there was a marked decrease in levels 3 and above and in other undesirable events when the elitericote (ii) was not head-to-head with the eliteron injection fluid。
In general, the pan-heroic-1 study, led by chinese experts, focuses on pancreatic cancer in china, and the research programme is better suited to the chinese population. The results of the study prove that the elettronics (ii) have good therapeutic efficacy and safety, provide strong evidence to support clinical practice for the follow-up of pancreatic second-line treatment, and ignite the survival hopes of patients with local advanced or transmissible pancreas cancer in the country。
Summary
As a nationally produced innovative drug, (ii) unique structural design has enabled it to display excellent therapeutic and low-toxic properties in clinical applications. Successful marketing of products represents a major breakthrough in china’s history of pancreas cancer treatment. The opening of the country's premiere marked the official clinical use of the product, which not only confirmed the value of the clinical application of ili tektor iv, but also demonstrated that the country's innovations in medicine will gradually benefit more people with pancreas cancer and bring new choices and light to them。
